Date: 2017-01-03
Type of information: Nomination
Compound: chief medical officer
Company: Alnylam Therapeutics (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On January 3, 2017, Alnylam Pharmaceuticals announced that David-Alexandre Gros, senior vice president and chief business officer, plans to leave the company for personal reasons. "My decision to leave is based on my personal interest to return to the West Coast in a broader operating role " said Dr. Gros. His resignation will be effective January 6, 2017 , and the company will initiate a search for his replacement.
- Additionally, the Company announced the promotion of Pushkal Garg , senior vice president, clinical development, to the role of chief medical officer, reporting to Akshay Vaishnaw , executive vice president of R&D. In his promotion, Dr. Garg will be responsible for clinical development at Alnylam, leading clinical research, clinical operations, biometrics, and medical writing functions. He will also join the company's management board.
Dr. Garg joined Alnylam in late 2014 with over 15 years of experience in early and late-stage clinical drug development, including at BMS and Millennium Pharmaceuticals . During his tenure at BMS, he was responsible for the development and successful global approvals of several medicines in the Immunoscience therapeutic area. He received a Bachelor of Arts from the University of California , Berkeley , and an M.D. from the University of California, San Francisco . He completed residency training in Internal Medicine at UCSF, was a research fellow at Johns Hopkins University , and served on the faculty of Harvard Medical School and the Brigham & Women's Hospital in Boston prior to joining industry.
Financial terms:
Latest news:
Is general: Yes
